Biotech Values

[DewDiligence]

ARAV +12% on phase-1b data in ovarian cancer:

https://www.globenewswire.com/news-release/2019/07/31/1894616/0/en/Aravive-Reports-Preliminary-Results-of-AVB-500-from-the-First-Cohort-of-the-Phase-1b-Phase-2-Recurrent-Platinum-Resistant-Ovarian-Cancer-Trial.html

AVB-500 (previously called AVB-S6-500) is a therapeutic recombinant fusion protein that has been shown to neutralize GAS6 activity by binding to GAS6 with very high affinity. In doing so, AVB-500 selectively inhibits the GAS6-AXL signaling pathway. In preclinical studies, GAS6-AXL inhibition has shown anti-tumor activity, both as a single agent or in combination with a variety of anticancer therapies including radiation therapy, immuno-oncology agents, and chemotherapeutic drugs that affect DNA replication and repair. Increased expression of AXL and GAS6 in tumors is correlated to poor prognosis and survival and has been implicated in therapeutic resistance to conventional chemotherapeutics and targeted therapies.